Gentium S.p.a. (GENT) Return on Assets ROA from the fourth quarter of 2013 to fourth quarter of 2012 and for the year 2013, Average High and Low, Fundamental Ratios from Dec 31 2013 to Dec 31 2012 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Gentium S.p.a.  (GENT)


Gentium S.p.a.'s ROA from the fourth quarter of 2013 to the fourth quarter of 2012 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Gentium S.p.a.'s ROA in the fourth quarter of 2013?
Gentium S.p.a. achieved a return on average assets (ROA) of 92.72 % in its fourth quarter of 2013, this is above GENT's average return on assets of -29.44%.
Gentium S.p.a. assets over the 12 months ending in its fourth quarter of 2013 are valued at $37 million

ROA has improved compared to -93.56% in the third quarter of 2013, due to net income growth.

However, within the Healthcare sector 46 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2013 from to 310.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2013)
IV. Quarter		 0
III. Quarter		 (Jun 30 2013)
II. Quarter		 0
I. Quarter		 (Dec 31 2012)
FY
Y / Y Total Assets Change 3.23 % -38.47 % 26.05 % 59.68 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 35 -35 -34 -64 -62
Return On Assets (TTM) 92.72 % -93.56 % -79.22 % -159.38 % -169.45 %
GENT's Total Ranking # 310 # # # # 4385
Total Assets (TTM) in million 36 34 45 34 35
Seq. Total Assets Change 4.35 % -22.92 % 29.73 % -1.07 % -37.8 %
Seq. Net Income Change - - - - -

GENT's 5 Years Annual ROA >> Back to GENT Management Effectiveness >> Compare GENT ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 10
Sector # 47
Overall # 229

Return On Assets Statistics
High Average Low
37.58 %
-29.44 %
-96.46 %
(Dec 31 2013)   (Dec 31 2012)





Financial Statements
Gentium S.p.a.'s Assets $ 36 million GENT's Balance sheet
Gentium S.p.a.'s Income $ 33 million Quarterly GENT's Income Statement
GENT's Income by Division See GENT's Income by Division



Annual Return On Assets (Dec 31 2013)
FY 2013		 (Dec 31 2012)
FY 2012		 (Dec 31 2009)
FY 2011
FY
FY
Y / Y Total Assets Change 8.87 % 178.91 % - - -
Total Assets in million 65 60 21 0 0
Y / Y Net Income Change - - - - -
Net Income in million 25 -36 -6 0 0
Annual Return On Assets 37.71 % -60.78 % -29.35 % - -

GENT's 5 Years Annual ROA >> Back to GENT Management Effectiveness >> Compare GENT ROA to its Competitors



Comment on GENT's ROA in the fiscal year ending 2013
In the fiscal year 2013 ROA improved to 37.71 % compared to prior year, due to annual net income growth of % to $24.60 million, while value of Gentium S.p.a.'s overall assets grew just by 8.87 % to $65.25 million, compared to $65.25 a year before.


More Return On Assets Ratios
GENT's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GENT's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GENT's Competitors
Subscribers only: Roa for Gentium S.p.a.'s Suppliers
Subscribers only: Return On Assets for GENT's Customers

You may also want to know
GENT's Roi GENT's Inventory Turnover Ratio GENT's Growth Rates GENT's Dividend Comparisons
GENT's Profitability Ratios GENT's Asset Turnover Ratio GENT's Dividend Growth
GENT's Roe GENT's Valuation Ratios GENT's Financial Strength Ratios GENT's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2013, within Healthcare Sector ROA
Therapeutic Solutions International Inc   173.88 %
Aratana Therapeutics, Inc.  143.79 %
Ontrak Inc   141.71 %
Fennec Pharmaceuticals Inc   137.69 %
Titan Pharmaceuticals Inc   120.16 %
Skinvisible Inc   120.13 %
Wearable Health Solutions, Inc.  111.20 %
Histogen Inc   111.05 %
Fuse Medical Inc   105.37 %
Brainstorm Cell Therapeutics inc   100.57 %
Cyclo Therapeutics Inc   99.82 %
Savara Inc   95.48 %
Bluebird Bio Inc   93.86 %
Epizyme Inc.  85.66 %
Biocorrx Inc   79.56 %
Glucotrack Inc   76.46 %
Cadence Pharmaceuticals Inc  75.25 %
China Yct International Group, Inc.  67.04 %
Sorrento Therapeutics Inc   65.91 %
Oramed Pharmaceuticals Inc  62.54 %
Filana Therapeutics Inc   60.10 %
Arena Pharmaceuticals Inc   59.86 %
Mymetics Corporation  53.63 %
Portola Pharmaceuticals inc   53.06 %
Lightwave Logic Inc   49.42 %
Agios Pharmaceuticals Inc   42.54 %
Gentium S.p.a.  37.58 %
Insys Therapeutics, Inc.  36.82 %
Veru Inc   36.44 %
Nephros Inc   35.32 %

Date modified: 2026-09-10T02:29:34+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.